Biology of Blood and Marrow Transplantation最新文献

{"title":"Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia","authors":"Leonardo Javier Arcuri ,&nbsp;Samir Kanaan Nabhan ,&nbsp;Renato Cunha ,&nbsp;Samantha Nichele ,&nbsp;Andreza Alice Feitosa Ribeiro ,&nbsp;Juliana Folloni Fernandes ,&nbsp;Liane Esteves Daudt ,&nbsp;Ana Luiza Melo Rodrigues ,&nbsp;Celso Arrais-Rodrigues ,&nbsp;Adriana Seber ,&nbsp;Elias Hallack Atta ,&nbsp;Jose Salvador Rodrigues de Oliveira ,&nbsp;Vaneuza Araujo Moreira Funke ,&nbsp;Gisele Loth ,&nbsp;Luiz Guilherme Darrigo Junior ,&nbsp;Alessandra Paz ,&nbsp;Rodolfo Froes Calixto ,&nbsp;Alessandra Araujo Gomes ,&nbsp;Carlos Eduardo Sa Araujo ,&nbsp;Vergilio Colturato ,&nbsp;Carmem Bonfim","doi":"10.1016/j.bbmt.2020.09.007","DOIUrl":"10.1016/j.bbmt.2020.09.007","url":null,"abstract":"<div><p>Severe aplastic anemia (SAA) is a life-threatening disease that can be cured with allogeneic cell transplantation (HCT). Haploidentical donor transplantation with post-transplantation cyclophosphamide (haplo-PTCy) is an option for patients lacking an HLA-matched donor. We analyzed 87 patients who underwent haplo-PTCy between 2010 and 2019. The median patient age was 14 years (range, 1 to 69 years), most were heavily transfused, and all received previous immunosuppression (25% without antithymocyte globulin). Almost two-thirds (63%) received standard fludarabine (Flu)/cyclophosphamide (Cy) 29/total body irradiation (TBI) 200 cGy conditioning, and the remaining patients received an augmented conditioning: Flu/Cy29/TBI 300-400 (16%), Flu/Cy50/TBI 200 (10%), or Flu/Cy50/TBI 400 (10%). All patients received PTCy-based graft-versus-host disease (GVHD) prophylaxis. Most grafts (93%) were bone marrow (BM). The median duration of follow-up was 2 years and 2 months. The median time to neutrophil recovery was 17 days. Primary graft failure occurred in 15% of the patients, and secondary or poor graft function occurred in 5%. The incidences of grade II-IV acute GVHD was 14%, and that of chronic GVHD was 9%. Two-year overall survival and event-free survival (EFS) were 79% and 70%, respectively. EFS was higher for patients who received augmented Flu/Cy/TBI (hazard ratio [HR], .28; <em>P</em> = .02), and those who received higher BM CD34 cell doses (&gt;3.2 × 10E6/kg) (HR, .29; <em>P</em> = .004). The presence of donor-specific antibodies before HSCT was associated with lower EFS (HR, 3.92; <em>P</em> = .01). Graft failure (HR, 7.20; <em>P</em> &lt; .0001) was associated with an elevated risk of death. Cytomegalovirus reactivation was frequent (62%). Haploidentical HCT for SAA is a feasible procedure; outcomes are improved with augmented conditioning regimens and BM grafts with higher CD34 cell doses.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2311-2317"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.09.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38397748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Regarding “Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma”","authors":"Jie Zhang ,&nbsp;Junlong Li ,&nbsp;Qiufei Ma ,&nbsp;Hongbo Yang ,&nbsp;James Signorovitch ,&nbsp;Eric Wu","doi":"10.1016/j.bbmt.2020.08.032","DOIUrl":"10.1016/j.bbmt.2020.08.032","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages e333-e334"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38400533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","authors":"Philip H. Imus ,&nbsp;Hua-Ling Tsai ,&nbsp;Amy E. DeZern ,&nbsp;Kevin Jerde ,&nbsp;Lode J. Swinnen ,&nbsp;Javier Bolaños-Meade ,&nbsp;Leo Luznik ,&nbsp;Ephraim J. Fuchs ,&nbsp;Nina Wagner-Johnston ,&nbsp;Carol Ann Huff ,&nbsp;Douglas E. Gladstone ,&nbsp;Richard F. Ambinder ,&nbsp;Christian B. Gocke ,&nbsp;Syed Abbas Ali ,&nbsp;Ivan M. Borrello ,&nbsp;Ravi Varadhan ,&nbsp;Robert Brodsky ,&nbsp;Richard J. Jones","doi":"10.1016/j.bbmt.2020.09.018","DOIUrl":"10.1016/j.bbmt.2020.09.018","url":null,"abstract":"<div><p>Transplant-associated thrombotic microangiopathy (taTMA) is a systemic vascular illness associated with significant morbidity and mortality, resulting from a convergence of risk factors after allogeneic blood or marrow transplantation (alloBMT). The diagnosis of taTMA has been a challenge, but most criteria include an elevated lactate dehydrogenase (LDH), low haptoglobin, and schistocytes on peripheral blood smear. We performed a retrospective review of the 678 consecutive adults who received high-dose post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis between January 1, 2015, and August 31, 2018. In April 2016, we initiated a monitoring program of weekly LDH and haptoglobin measurements and blood smears when those 2 parameters were both abnormal on all of our adult patients undergoing alloBMT for hematologic malignancies. During the entire period, the 1-year cumulative incidence of taTMA was 1.4% (95% confidence interval, 0.5% to 2.3%). Eight patients were taking tacrolimus at the time of diagnosis, and 1 was not on any immunosuppression. Eight of 9 patients (89%) were hypertensive. Four patients had invasive infections at the time of diagnosis, 4 patients required renal replacement therapy, and 5 of 9 patients were neurologically impaired. Eculizumab was given to 6 patients (0.9%), of whom 2 died and 4 recovered with resolution of end-organ dysfunction. The paucity of events made the determination of risk factors difficult; however, the low incidence of taTMA in this cohort may be related to the limited use of myeloablative conditioning regimens, low incidence of severe GVHD, and use of PTCy. PTCy-based GVHD prophylaxis appears to be associated with a low incidence of severe taTMA.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 12","pages":"Pages 2306-2310"},"PeriodicalIF":4.3,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.09.018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38503564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Early Supportive Care Needs among Son or Daughter Haploidentical Transplantation Donors","authors":"Nina D. Wagner-Johnston ,&nbsp;Susan M. Hannum ,&nbsp;JaAlah-Ai Heughan ,&nbsp;Martha Abshire ,&nbsp;Jennifer L. Wolff ,&nbsp;Kathryn Yarkony ,&nbsp;Heather Symons ,&nbsp;Richard J. Jones ,&nbsp;Sydney M. Dy","doi":"10.1016/j.bbmt.2020.08.005","DOIUrl":"10.1016/j.bbmt.2020.08.005","url":null,"abstract":"<div><p>Increasingly, adolescent, young adult, and adult children are relied upon as donors for their parents undergoing blood and marrow stem cell transplant. How family functioning impacts donors’ decision making and whether haploidentical donor children have unique supportive care needs is unknown. In this qualitative research study, we conducted 15 semistructured telephone interviews among individuals who underwent blood or marrow stem cell donation for their parent. Interviews explored donors’ perspectives of the transplant experience across the trajectory from screening through early post-transplant follow-up and elicited unmet needs. Major themes included: (<span>1</span>) perception of choice, (<span>2</span>) act of giving back, (<span>3</span>) burdens of donation, (<span>4</span>) anticipated health benefit to parent, and (<span>5</span>) impact of donation on parent/child relationship. The majority of participants described high family functioning, but strain was also evident. Family functioning rarely was reported as affecting the decision to donate, with all donors expressing a sense of obligation. Participants were overwhelmingly satisfied with their decision and the ability to give back to their parent. Suggestions for the health care team to improve the donation experience focused on increased education about potential delays in screening, better description of possible complications for recipients, and provision of emotional support following donation.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2121-2126"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10669802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes","authors":"Aziz Nazha ,&nbsp;Zhen-Huan Hu ,&nbsp;Tao Wang ,&nbsp;R. Coleman Lindsley ,&nbsp;Hisham Abdel-Azim ,&nbsp;Mahmoud Aljurf ,&nbsp;Ulrike Bacher ,&nbsp;Asad Bashey ,&nbsp;Jean-Yves Cahn ,&nbsp;Jan Cerny ,&nbsp;Edward Copelan ,&nbsp;Zachariah DeFilipp ,&nbsp;Miguel Angel Diaz ,&nbsp;Nosha Farhadfar ,&nbsp;Shahinaz M. Gadalla ,&nbsp;Robert Peter Gale ,&nbsp;Biju George ,&nbsp;Usama Gergis ,&nbsp;Michael R. Grunwald ,&nbsp;Betty Hamilton ,&nbsp;Wael Saber","doi":"10.1016/j.bbmt.2020.08.003","DOIUrl":"10.1016/j.bbmt.2020.08.003","url":null,"abstract":"<div><p>Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes (MDS). Mortality after HCT is high, with deaths related to relapse or transplant-related complications. Thus, identifying patients who may or may not benefit from HCT is clinically important. We identified 1514 patients with MDS enrolled in the Center for International Blood and Marrow Transplant Research Registry and had their peripheral blood samples sequenced for the presence of 129 commonly mutated genes in myeloid malignancies. A random survival forest algorithm was used to build the model, and the accuracy of the proposed model was assessed by concordance index. The median age of the entire cohort was 59 years. The most commonly mutated genes were <em>ASXL1</em>(20%), <em>TP53</em> (19%), <em>DNMT3A</em> (15%), and <em>TET2</em> (12%). The algorithm identified the following variables prior to HCT that impacted overall survival: age, <em>TP53</em> mutations, absolute neutrophils count, cytogenetics per International Prognostic Scoring System–Revised, Karnofsky performance status, conditioning regimen, donor age, WBC count, hemoglobin, diagnosis of therapy-related MDS, peripheral blast percentage, mutations in RAS pathway, <em>JAK2</em> mutation, number of mutations/sample, <em>ZRSR2</em>, and <em>CUX1</em> mutations. Different variables impacted the risk of relapse post-transplant. The new model can provide survival probability at different time points that are specific (personalized) for a given patient based on the clinical and mutational variables that are listed above. The outcomes’ probability at different time points may aid physicians and patients in their decision regarding HCT.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2139-2146"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38261085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide","authors":"Amy E. DeZern ,&nbsp;Hany Elmariah ,&nbsp;Marianna Zahurak ,&nbsp;Gary L. Rosner ,&nbsp;Douglas E. Gladstone ,&nbsp;Syed Abbas Ali ,&nbsp;Carol Ann Huff ,&nbsp;Lode J. Swinnen ,&nbsp;Phil Imus ,&nbsp;Ivan Borrello ,&nbsp;Nina D. Wagner-Johnston ,&nbsp;Richard F. Ambinder ,&nbsp;Robert A. Brodsky ,&nbsp;Kenneth Cooke ,&nbsp;Leo Luznik ,&nbsp;Ephraim J. Fuchs ,&nbsp;Javier Bolaños-Meade ,&nbsp;Richard J. Jones","doi":"10.1016/j.bbmt.2020.07.037","DOIUrl":"10.1016/j.bbmt.2020.07.037","url":null,"abstract":"<div><p>With post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis, nonmyeloablative (NMA) HLA-haploidentical (haplo) and HLA-matched blood or marrow transplantation (BMT) have comparable outcomes. Previous reports have shown that discontinuation of immunosuppression (IS) as early as day 60 after infusion of a bone marrow (BM) haplo allograft with PTCy is feasible. There are certain diseases in which peripheral blood (PB) may be favored over BM, but given the higher rates of GVHD with PB, excessive GVHD is of increased concern. We report a completed, prospective single-center trial of stopping IS at days 90 and 60 after NMA PB stem cell transplantation (PBSCT). Between 12/2015-7/2018, 117 consecutive patients with hematologic malignancies associated with higher rates of graft failure after NMA conditioned BMT and PTCy, received NMA PB allografts on trial. The primary objective of this study was to evaluate the safety and feasibility of reduced‐duration IS (from day 5 through day 90 in the D90 cohort and through day 60 in the D60 cohort). Of the 117 patients (median age, 64 years; range, 22 to 78 years), the most common diagnoses were myelodysplastic syndrome (33%), acute myelogenous leukemia (with minimal residual disease or arising from an antecedent disorder) (32%), myeloproliferative neoplasms (19%), myeloma (9%), and chronic lymphoblastic leukemia (7%). Shortened IS was feasible in 75 patients (64%) overall. Ineligibility for shortened IS resulted most commonly from GVHD (17 patients), followed by early relapse (11 patients), nonrelapse mortality (NRM) (7 patients), patient/ physician preference (4 patients) or graft failure (3 patients). Of the 57 patients in the D90 cohort, 33 (58%) stopped IS early as planned, and among the 60 patients in the D60 cohort, 42 (70%) stopped IS early as planned. The graft failure rate was 2.6%. After IS cessation, the median time to diagnosis of grade II-IV acute GVHD was 21 days in the D90 cohort and 32 days in the D60 cohort, with almost all cases developing within 40 days. Approximately one-third of these patients resumed IS. All outcome measures were similar in the 2 cohorts and our historical outcomes with 180 days of IS. The cumulative incidence of grade III-IV acute GVHD was low, 2% in the D90 cohort and 7% in the D60 cohort. The incidence of severe chronic GVHD at 2 years was 9% in the D90 cohort and 5% in the D60 cohort. The 2-year overall survival was 67% for both the D90 and D60 cohorts. The 2-year progression-free survival was 47% for the D90 cohort and 52% for the D60 cohort, and the GVHD-free, relapse-free survival was &lt;35% for both cohorts. These data suggest that reduced-duration IS in patients undergoing NMA PBSCT with PTCy is feasible and has an acceptable safety profile.</p><p>© 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2075-2081"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38281572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes","authors":"Tania Jain,&nbsp;Amy E. DeZern","doi":"10.1016/j.bbmt.2020.09.012","DOIUrl":"10.1016/j.bbmt.2020.09.012","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages e263-e264"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1083879120305723/pdfft?md5=f6121879bf723e37133ce526f5b2f9a4&pid=1-s2.0-S1083879120305723-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38406251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation","authors":"John S. Tanaka ,&nbsp;Rebecca R. Young ,&nbsp;Sarah M. Heston ,&nbsp;Kirsten Jenkins ,&nbsp;Lisa P. Spees ,&nbsp;Anthony D. Sung ,&nbsp;Kelly Corbet ,&nbsp;Jillian C. Thompson ,&nbsp;Lauren Bohannon ,&nbsp;Paul L. Martin ,&nbsp;Andre Stokhuyzen ,&nbsp;Richard Vinesett ,&nbsp;Doyle V. Ward ,&nbsp;Shakti K. Bhattarai ,&nbsp;Vanni Bucci ,&nbsp;Mehreen Arshad ,&nbsp;Patrick C. Seed ,&nbsp;Matthew S. Kelly","doi":"10.1016/j.bbmt.2020.07.011","DOIUrl":"10.1016/j.bbmt.2020.07.011","url":null,"abstract":"<div><p>Certain anaerobic bacteria are important for maintenance of gut barrier integrity and immune tolerance and may influence the risk of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a single-center retrospective cohort study of allogeneic HSCT recipients to evaluate associations between receipt of antibiotics with an anaerobic spectrum of activity and GVHD outcomes. We identified 1214 children and adults who developed febrile neutropenia between 7 days before and 28 days after HSCT and compared GVHD risk and mortality among patients who received anaerobic antibiotics (piperacillin-tazobactam or carbapenems; n = 491) to patients who received only antibiotics with minimal activity against anaerobes (aztreonam, cefepime, or ceftazidime; n = 723). We performed metagenomic sequencing of serial fecal samples from 36 pediatric patients to compare the effects of specific antibiotics on the gut metagenome. Receipt of anaerobic antibiotics was associated with higher hazards of acute gut/liver GVHD (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.03 to 1.54) and acute GVHD mortality (HR, 1.63; 95% CI, 1.08 to 2.46), but not chronic GVHD diagnosis (HR, 1.04; 95% CI: .84 to 1.28) or chronic GVHD mortality (HR, .88; 95% CI, .53 to 1.45). Anaerobic antibiotics resulted in decreased gut bacterial diversity, reduced abundances of Bifidobacteriales and Clostridiales, and loss of bacterial genes encoding butyrate biosynthesis enzymes from the gut metagenome. Acute gut/liver GVHD was preceded by a sharp decline in bacterial butyrate biosynthesis genes with antibiotic treatment. Our findings demonstrate that exposure to anaerobic antibiotics is associated with increased risks of acute gut/liver GVHD and acute GVHD mortality after allogeneic HSCT. Use of piperacillin-tazobactam or carbapenems should be reserved for febrile neutropenia cases in which anaerobic or multidrug-resistant infections are suspected.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2053-2060"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38167338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Masthead (Purpose and Scope)","authors":"","doi":"10.1016/S1083-8791(20)30633-9","DOIUrl":"https://doi.org/10.1016/S1083-8791(20)30633-9","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Page A5"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1083-8791(20)30633-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137415557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide","authors":"Ignacio Gómez-Centurión ,&nbsp;Rebeca Bailén ,&nbsp;Gillen Oarbeascoa ,&nbsp;Cristina Muñoz ,&nbsp;Arturo Álvarez Luque ,&nbsp;Miguel Echenagusia Boyra ,&nbsp;Enrique Calleja ,&nbsp;Diego Rincón ,&nbsp;Nieves Dorado ,&nbsp;Paola Barzallo ,&nbsp;Javier Anguita ,&nbsp;José Luis Díez-Martín ,&nbsp;Mi Kwon","doi":"10.1016/j.bbmt.2020.08.006","DOIUrl":"10.1016/j.bbmt.2020.08.006","url":null,"abstract":"<div><p>Hepatic veno-occlusive disease or sinusoidal obstruction syndrome (VOD/SOS) is a threatening complication after both autologous and allogeneic hematopoietic stem cell transplantation (HSCT), with high mortality rates despite early medical treatment, including the use of defibrotide (DF). We retrospectively analyzed 185 unmanipulated haploidentical (haplo-) HSCT with post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis performed consecutively between 2011 and June 2019 in a single center. Seventeen patients (9.2%) were diagnosed with VOD/SOS. Based on revised European Society for Blood and Marrow Transplantation severity criteria, the VOD/SOS cases were classified as mild in 2 patients (11.7%), moderate in 2 (11.7%), severe in 2 (11.7%), and very severe in 11 (64.9%). Thirteen patients (76%) were treated with DF, including all patients with severe or very severe VOD/SOS, except 1 patient with CNS hemorrhage. Sixteen patients (94%) were alive at day +100 after HSCT. Seven patients (41%) with very severe VOD/SOS were treated with transjugular intrahepatic portosystemic shunt (TIPS) owing to rapid clinical or analytical deterioration or refractory hepatorenal syndrome despite medical treatment, including DF. TIPS insertion was performed at a median time since VOD/SOS diagnosis of 4 days (range, 1 to 28 days) without technical complications in any case. The median hepatic venous pressure gradient before and after TIPS treatment was 24 mmHg (range, 14 to 29 mmHg) and 7 mmHg (range, 2 to 11 mmHg), respectively, with a median drop of 16 mmHg (range, 9 to 19 mmHg). Following TIPS insertion, all patients showed clinical improvement with hepatomegaly, ascites, and renal failure resolution, and all showed analytical improvement with reduced alanine aminotransferase (ALT), creatinine, and international normalized ratio values, except for patient 2, whose indication for TIPS was refractory hepatorenal syndrome with a normal ALT level. The 6 patients who had initiated DF before TIPS insertion completed 21 days of treatment. All patients met the criteria for complete remission (CR) at a median of 8 days after TIPS insertion (range, 2 to 82 days). The 100-day overall survival was 100%. For patients with rapid progressive VOD/SOS, early TIPS insertion allowed completion of DF therapy. The use of TIPS together with DF resulted in CR and no associated complications with no VOD/SOS-associated mortality despite high severity. In our experience, timely and individualized use of TIPS significantly improves outcomes of very severe VOD/SOS after haplo-HSCT. Therefore, TIPS should be promptly considered in rapidly progressive cases.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2089-2097"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38260006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}